At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Observational, Multicentre Study Evaluating HCV Patients Characteristics of Eligibility and Disease Management in Real Clinical Practice
In Brief
An observational study evaluating Peginterferon alfa-2b, Ribavirin, and 1 other intervention for Hepatitis C and Hepatitis C, Chronic. Completed, enrolled 1,128 participants.
Detailed Summary
The goal of this study is to elucidate the reasons why patients with chronic hepatitis C (CHC) would not be considered eligible for antiviral treatment. The study is conducted in common clinical practice at approximately 54 sites in Italy. Patients deemed eligible for antiviral therapy will be treated at the discretion of the physician with either peginterferon alfa-2a or peginterferon alfa-2b, both in combination with ribavirin, in accordance with approved labeling. A secondary objective of this study is to define "treatment failure" and to evaluate the reasons for treatment discontinuation.
Study Details
Timeline
Interventions
Peginterferon alfa-2b administered in accordance with approved labeling
Ribavirin administered in accordance with approved labeling
Peginterferon alfa-2a administered in accordance with approved labeling